Therapeutic approach using analysis of type III IFN SNPs in upper respiratory disease

呼吸道合胞病毒（RSV）是呼吸道疾病的主要病原。人鼻粘膜上皮是呼吸道病毒感染的第一道防线。RSV可从顶侧而非基底侧感染这些细胞，并增强了紧密连接蛋白的表达。RSV感染诱导受感染细胞的极性，从而传播感染。作为针对不同病毒感染的先天免疫应答，宿主诱导两种类型的IFN，I型和III型。III型，而不是I型，有助于鼻粘膜中抵抗呼吸道病毒感染的主要第一线防御。姜黄素和Humulon能抑制RSV的复制和上皮细胞对RSV的反应，克拉霉素还能抑制RSV诱导的PAF受体表达和荧光素标记的S. pneumoniae细胞对A549细胞的增殖。这些是用于预防和治疗RSV感染的有用生物制品。

Respiratory syncytial virus (RSV) is the major cause of respiratory disease. The human nasal epithelium is the first line of defense during respiratory virus infection. RSV could infect these cells from apical but not basolateral side, and enhanced the expression of tight junction proteins. RSV infection induces polarity in the infected cells, thereby spreading the infection.As an innate immune response against diverse viral infections, a host induces two types of IFN, type-I and type-III. Type -III, but not type-I, contributes to the main first line defense against respiratory virus infection in nasal mucosa. Curcumin and Humulon can prevent the replication of RSV and the epithelial responses to it. Moreover, Clarithromycin also suppressed RSV-induced PAF receptor expression and adhesion of fluorescein-labeled S. pneumoniae cells to A549 cells. These are useful biological products for the prevention and therapy for RSV infection.